InsidersTradesSigma
Track the Atrium Therapeutics, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €219.6m. The latest transaction was disclosed on 22 April 2026 (Attribution). Among the most active insiders: Younis Husam. All data is openly available.
Analysts rate Atrium Therapeutics, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$25.00.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
Atrium Therapeutics, Inc. is a company focused on developing innovative treatments for cardiovascular diseases. It is listed on the NASDAQ under the ticker symbol ATRM.